Thirdly, a comparative assessment of the efficacy and safety between the ABCP regimen and the platinum doublet regimen in EGFR-positive (exon 19 deletion or L858R mutation) non-squamous NSCLC patients was not conducted, given the retrospective, single-arm design of this study. This evidence concerns the gene EGFR and non-small cell lung carcinoma.